The role of IDH1/2 mutations in the pathogenesis of secondary glioblastomas

ABSTRACT Diffuse astrocytoma and glioblastoma (GBM) constitute a group of diffusely infiltrating astrocytic neoplasms, which more commonly arise in cerebral hemispheres of adults. The prevalence of malignant transformation of diffuse astrocytoma to anaplastic astrocytoma and GBM varies from 40% to 7...

Full description

Bibliographic Details
Main Author: Eduardo Cambruzzi
Format: Article
Language:English
Published: Sociedade Brasileira de Patologia Clínica 2017-10-01
Series:Jornal Brasileiro de Patologia e Medicina Laboratorial
Subjects:
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1676-24442017000500338&tlng=en
_version_ 1818975413563555840
author Eduardo Cambruzzi
author_facet Eduardo Cambruzzi
author_sort Eduardo Cambruzzi
collection DOAJ
description ABSTRACT Diffuse astrocytoma and glioblastoma (GBM) constitute a group of diffusely infiltrating astrocytic neoplasms, which more commonly arise in cerebral hemispheres of adults. The prevalence of malignant transformation of diffuse astrocytoma to anaplastic astrocytoma and GBM varies from 40% to 75% of cases in different series. Distinct genetic abnormalities are related to neoplastic progression, and the cells prone to glial neoplasm development include progenitor cells, stem cells, or differentiated cells. Primary GBM arises typically de novo, with no previous history of a lower-grade precursor lesion. Secondary GBM evolves from low-grade astrocytoma, is predominant in younger patients, and frequently exhibits isocitrate dehydrogenase (IDH) 1 and 2 mutations. IDH1/2 mutated gliomas have been associated with a better prognosis when compared to IDH-wildtype gliomas. IDH mutations are rare in primary GBM and gliomas arising in children. Evidence suggests that IDH mutations lead to a hypermethylation phenotype and represent early events in tumoral transformation of the central nervous system (CNS) due to the production of the oncometabolite 2-hydroxyglutarate. IDH1 mutations precede tumor protein p53 (TP53) mutations in around 63% of cases of diffuse astrocytomas, and result in loss in 10q and 19q chromosomes. Primary GBMs are also associated with alterations in cell proliferation [epidermal growth fator receptor (EGFR) amplification/mutation, platelet derived growth factor receptor alpha (PDGFRA) amplifications, neurofibromin 1 (NF1) mutations], abnormal apoptotic index [cyclin dependent kinase inhibitor 2A (CDKN2A) homozygous deletion and TP53 mutation], and aberrant progression in G1/S phase of the cell cycle.
first_indexed 2024-12-20T15:55:34Z
format Article
id doaj.art-342226e0898b438492fd99e7608c6c09
institution Directory Open Access Journal
issn 1678-4774
language English
last_indexed 2024-12-20T15:55:34Z
publishDate 2017-10-01
publisher Sociedade Brasileira de Patologia Clínica
record_format Article
series Jornal Brasileiro de Patologia e Medicina Laboratorial
spelling doaj.art-342226e0898b438492fd99e7608c6c092022-12-21T19:34:28ZengSociedade Brasileira de Patologia ClínicaJornal Brasileiro de Patologia e Medicina Laboratorial1678-47742017-10-0153533834410.5935/1676-2444.20170055The role of IDH1/2 mutations in the pathogenesis of secondary glioblastomasEduardo CambruzziABSTRACT Diffuse astrocytoma and glioblastoma (GBM) constitute a group of diffusely infiltrating astrocytic neoplasms, which more commonly arise in cerebral hemispheres of adults. The prevalence of malignant transformation of diffuse astrocytoma to anaplastic astrocytoma and GBM varies from 40% to 75% of cases in different series. Distinct genetic abnormalities are related to neoplastic progression, and the cells prone to glial neoplasm development include progenitor cells, stem cells, or differentiated cells. Primary GBM arises typically de novo, with no previous history of a lower-grade precursor lesion. Secondary GBM evolves from low-grade astrocytoma, is predominant in younger patients, and frequently exhibits isocitrate dehydrogenase (IDH) 1 and 2 mutations. IDH1/2 mutated gliomas have been associated with a better prognosis when compared to IDH-wildtype gliomas. IDH mutations are rare in primary GBM and gliomas arising in children. Evidence suggests that IDH mutations lead to a hypermethylation phenotype and represent early events in tumoral transformation of the central nervous system (CNS) due to the production of the oncometabolite 2-hydroxyglutarate. IDH1 mutations precede tumor protein p53 (TP53) mutations in around 63% of cases of diffuse astrocytomas, and result in loss in 10q and 19q chromosomes. Primary GBMs are also associated with alterations in cell proliferation [epidermal growth fator receptor (EGFR) amplification/mutation, platelet derived growth factor receptor alpha (PDGFRA) amplifications, neurofibromin 1 (NF1) mutations], abnormal apoptotic index [cyclin dependent kinase inhibitor 2A (CDKN2A) homozygous deletion and TP53 mutation], and aberrant progression in G1/S phase of the cell cycle.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1676-24442017000500338&tlng=enastrocytomaglioblastomaisocitrate dehydrogenasepathologyprognosisbrain
spellingShingle Eduardo Cambruzzi
The role of IDH1/2 mutations in the pathogenesis of secondary glioblastomas
Jornal Brasileiro de Patologia e Medicina Laboratorial
astrocytoma
glioblastoma
isocitrate dehydrogenase
pathology
prognosis
brain
title The role of IDH1/2 mutations in the pathogenesis of secondary glioblastomas
title_full The role of IDH1/2 mutations in the pathogenesis of secondary glioblastomas
title_fullStr The role of IDH1/2 mutations in the pathogenesis of secondary glioblastomas
title_full_unstemmed The role of IDH1/2 mutations in the pathogenesis of secondary glioblastomas
title_short The role of IDH1/2 mutations in the pathogenesis of secondary glioblastomas
title_sort role of idh1 2 mutations in the pathogenesis of secondary glioblastomas
topic astrocytoma
glioblastoma
isocitrate dehydrogenase
pathology
prognosis
brain
url http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1676-24442017000500338&tlng=en
work_keys_str_mv AT eduardocambruzzi theroleofidh12mutationsinthepathogenesisofsecondaryglioblastomas
AT eduardocambruzzi roleofidh12mutationsinthepathogenesisofsecondaryglioblastomas